Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer

Executive Summary

AstraZeneca and Merck & Co hope to advance Lynparza quickly in prostate and pancreatic cancers after getting first mover advantage in metastatic breast cancer.

You may also be interested in...



AstraZeneca/Merck’s Lynparza Is First Adjuvant Option For BRCA-Positive Breast Cancer

One of two PARP inhibitors approved in breast cancer, Lynparza may have the adjuvant breast indication all to itself for a while. One analyst projects a $1.5bn revenue opportunity for the indication.

Ovarian Cancer Market Snapshot: AstraZeneca's Lynparza Poised To Lead In Niche Space

AstraZeneca's Lynparza, Tesaro's Zejula and Clovis' Rubraca have brought much needed advances to patients with ovarian cancer, but the market is relatively small and the competition intense, while unmet need remains high.

First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo

Keytruda sales are soaring on first-line lung cancer use, but with many new filings and approvals, Merck tells its second-quarter earnings call it's just the beginning.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel